13 results on '"Wang, Guige"'
Search Results
2. LncRNA HCG11 Suppresses Cell Proliferation and Promotes Apoptosis via Sponging miR-224-3p in Non-Small-Cell Lung Cancer Cells.
- Author
-
Wang, Guige, Liu, Lei, Zhang, Jiaqi, Huang, Cheng, Chen, Yeye, Bai, Wenliang, Wang, Yanqing, Zhao, Ke, and Li, Shanqing
- Subjects
- *
NON-small-cell lung carcinoma , *CANCER cells , *CELL proliferation , *APOPTOSIS , *PATHOLOGY - Abstract
Introduction: Studies have found that Lnc-HCG11 is an important regulator of cancer. However, the function of Lnc-HCG11 in NSCLC is not known. Therefore, this experimental design was based on Lnc-HCG11 to explore the pathogenesis of NSCLC. Methods: RT-qPCR was used to detect the expression of Lnc-HCG11 and miR-224-3p in NSCLC. The effects of Lnc-HCG11 and miR-224-3p on proliferation and apoptosis of NSCLC cells were detected by CCK-8 assay, Edu assay and Annexin V-FITC/PI assay. Target gene prediction and screening, luciferase reporter assays were used to verify downstream target genes for lnc-HCG11 and miR-224-3p. Western blotting was used to detect the protein expression of caspase-3. The tumor changes in mice were detected by in vivo. Results: Lnc-HCG11 was significantly reduced in NSCLC. Lnc-HCG11 significantly inhibited cell proliferation of NSCLC cells and induced apoptosis. miR-224-3p was significantly elevated in the NSCLC cell line. Moreover, miR-224-3p significantly increased cell proliferation and inhibited apoptosis of NSCLC cells. Furthermore, Lnc-HCG11 was negatively correlated with miR-224-3p expression. Lnc-HCG11 over-expression was up-regulated the expression levels of c-caspase-3 and caspase-3. Finally, the results of in vivo animal models confirmed that Lnc-HCG11 inhibited tumor growth by modulating the miR-224-3p/c-caspase-3 axis. Conclusion: Lnc-HCG11 could inhibit the progression of NSCLC by modulating the miR-224-3p/caspase-3 axis, and Lnc-HCG11 may be a potential therapeutic target for NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. The 100 most cited papers on thymoma: a bibliometric analysis.
- Author
-
Liu, Lei, Zhang, Jiaqi, Wang, Guige, Zhao, Ke, Guo, Chao, Huang, Cheng, Li, Shanqing, and Chen, Yeye
- Subjects
- *
BIBLIOMETRICS , *THYMOMA , *SCIENCE databases , *WEB databases , *THORACIC surgery - Abstract
Objectives: The aim of this bibliometric analysis was twofold: to identify the 100 most cited research articles on thymoma and to highlight future research opportunities in light of past and current research efforts. Methods: The Web of Science database was queried to identify the 100 most cited articles on thymoma. Imformations relevant to scientific research were extracted and analyzed: first author, journal, impact factor, type of article, year of publication, country, organization and keywords. Results: The publication year of the top 100 most cited articles ranged from 1981 to 2018, and the number of citations ranged from 97 to 1182. Most of the included articles are original (75/100) and are mainly retrospective studies (52/75). The United States has the most published articles and citations, and the Annals of Thoracic Surgery is the most sourced journal (n = 16). Through VOSviewer analysis, high-density keywords mainly come from thymic carcinoma/invasive thymoma management, immune-related diseases, and laboratory research. Conclusions: To our knowledge, this is the first bibliometric study on thymoma. We found most of the top 100 most cited articles are original and retrospective research. The United States has the published and cited works. Presently, the hot keywords for thymoma research has gradually tilted towards immune-related diseases and laboratory research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Delayed Discharge after Thoracic Surgery under the Guidance of ERAS Protocols.
- Author
-
Liu, Lei, Zhang, Jiaqi, Wang, Guige, Guo, Chao, Chen, Yeye, Huang, Cheng, and Li, Shanqing
- Subjects
- *
CHRONIC obstructive pulmonary disease , *FORCED expiratory volume , *POSTOPERATIVE care , *CORONARY artery disease , *CHRONIC kidney failure - Abstract
Background Enhanced recovery after surgery (ERAS) protocols have been applied in thoracic surgery and are beneficial to patients. However, some issues about ERAS are still pending. Methods A total of 1,654 patients who underwent thoracic surgery under the guidance of ERAS protocols were enrolled in this study. We set the length of postoperative stay (LOPS) as our key research indicator. Patients were divided into routine discharge group and delayed discharge group based on LOPS. Causes of delayed discharge were analyzed to improve management of postoperative recovery. Results Male, old age, underlying disease (coronary artery disease, chronic kidney disease, old cerebral infarction, chronic obstructive pulmonary disease, and arrhythmia), intensive care unit (ICU) stay, type of insurance, and lower forced expiratory volume in one second (FEV1) are the independent impact factors causing delayed discharge. Increased nonchylous drainage (INCD) and prolonged air leakage were the two leading causes for delayed discharge. Conclusion Patients should have personalized recovery goal under the same ERAS protocols. We should accept that patients in poor general condition have a prolonged LOPS. More stringent ICU stay indications should be developed to increase postoperative patients' ERAS protocols compliance. Further research on chest tube management will make a contribution to ERAS protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Prognostic factors of T2aN0M0 (T3‐4cmN0M0, stage IB) non‐small‐cell lung cancer after surgery: Single‐center real‐world research.
- Author
-
Liu, Lei, Zhang, Jiaqi, Wang, Guige, Zhao, Ke, Guo, Chao, Chen, Yeye, Huang, Cheng, and Li, Shanqing
- Abstract
Aim Methods Results Conclusions To further elucidate the prognostic factors of non‐small‐cell lung cancer (NSCLC) patients with T2aN0M0 (stage IB) who underwent surgical treatment.We retrospectively analyzed the data of stage IB NSCLC patients who underwent surgical treatment at our center from October 2013 to September 2016. Eighty patients were enrolled. We analyzed their overall survival (OS) and disease‐free survival (DFS) using the Kaplan–Meier method.In univariable analysis, adenosquamous carcinoma (ASC) was significantly associated with inferior DFS (p = 0.036, p = 0.037) and OS (p = 0.001, p = 0.003) in all stage IB patients and those who only accepted surgery. Patients with a number of N2 lymph node dissections of ≥3 regions (N2‐LSNDr) exhibited better DFS (p = 0.020, p = 0.005) and OS (p = 0.003, p = 0.001) in all stage IB patients and those who only accepted surgery. In addition, advanced age (≥70 years old) is an adverse factor for DFS (p = 0.049) and OS (p = 0.018) among patients who did not receive adjuvant chemotherapy following surgery. In multivariable analyses, patients with N2‐LSNDr exhibited a longer OS (p = 0.045) in all enrolled patients; patients with N2‐LSNDr (p = 0.016) and younger age (p = 0.021) demonstrated a superior OS in patients who only received surgery.We found that N2‐LSNDr were independent influencing factors affecting the prognosis in all included stage IB patients and stage IB patients without adjuvant chemotherapy. ASC was associated with worse prognosis of T2aN0M0 NSCLC. Older age is an independent prognostic factor of the worst OS in stage IB patients without adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. New perspective to evaluate N1 staging: The peripheral lymph node metastasis status of non‐small cell lung cancer.
- Author
-
Zhang, Jiaqi, Liu, Lei, Wang, Guige, Huang, Cheng, Chen, Yeye, Zhang, Ye, Guo, Chao, and Li, Shanqing
- Subjects
- *
LUNG cancer diagnosis , *LUNG cancer treatment , *CANCER invasiveness , *COMBINED modality therapy , *LUNG cancer , *LYMPH nodes , *MEDICAL records , *METASTASIS , *TUMOR classification , *DECISION making in clinical medicine , *RETROSPECTIVE studies , *ACQUISITION of data methodology , *SOLITARY pulmonary nodule , *THORACOTOMY , *EVALUATION - Abstract
Background: Lymph node (LN) metastasis status is the decision‐making basis for the surgical procedure and adjuvant therapy modalities. Fewer studies have previously focused on LN metastasis in N1 station, especially on peripheral lymph node (PLN) metastasis in N1 station. This study aimed to reveal the metastasis status of PLN of non‐small cell lung cancer (NSCLC), and investigate its effects on N staging. Methods: We retrospectively evaluated a consecutive series of patients who underwent curative resection for histologically confirmed N1 NSCLC. Propensity score matching (PSM) was used to analyze the effects of PLN on N staging. Results: A total of 105 patients with confirmed pathological N1 (pN1) stage NSCLC with solitary nodule and without neoadjuvant therapy were enrolled into the study: 55 patients had intraperipheral LN metastasis (IPLNM), and 50 patients had extra‐peripheral LN metastasis (EPLNM). Before PSM analysis, type of location (P = 0.002), surgical procedure (P = 0.008), number of positive LNs (P = 0.029), number of LNs removed (P = 0.010), lobe of lung cancer (P = 0.031), and vascular invasion (P = 0.049) showed significant differences between the two groups. After PSM analysis, statistically there were differences in type of location (P = 0.034), number of positive LNs (P = 0.008) and vascular invasion (P = 0.049) between them. Conclusion: PLN metastasis was a quite common pattern of LN metastasis in N1 station of NSCLC. IPLNM occurred more frequently in central NSCLC and NSCLC with vascular invasion, and thoracotomy was likely to secure more accurate PLN staging. Clinicians should pay great attention to PLN dissection. Follow‐up data will be needed in order to detect the prognosis of IPLNM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Real‐world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma.
- Author
-
Zhao, Ke, Chen, Yeye, Liu, Lei, Wang, Guige, Zhang, Jiaqi, Zhou, Mengxin, Gao, Xuehan, Rao, Ke, Yang, Libing, Guo, Chao, Zhang, Ye, Huang, Cheng, Liu, Hongsheng, and Li, Shanqing
- Subjects
- *
THYMOMA , *TIME , *MULTIVARIATE analysis , *RETROSPECTIVE studies , *CANCER relapse , *METASTASIS , *TREATMENT effectiveness , *TUMOR classification , *KAPLAN-Meier estimator , *DESCRIPTIVE statistics , *RESEARCH funding , *PROGRESSION-free survival , *OVERALL survival , *PROPORTIONAL hazards models - Abstract
Background: This study aimed to examine the treatment and prognosis of patients with type B2 + B3 thymoma and compare it with those patients with type B2 and B3 thymoma. Methods: We conducted a retrospective analysis of the results of 39 patients with type B2 + B3 thymoma, 133 patients with type B2 thymoma, and 64 patients with type B3 thymoma. The Kaplan–Meier technique was used to generate survival curves. For multivariate analysis, the Cox proportional hazard model was applied. Results: With a median follow‐up of 60 months (range: 1–128 months), the percentage of patients with tumor, node, metastasis (TNM) stage III and IV disease gradually increased from 19.5% to 25.6% to 35.9% among those with histological subtypes B2, B2 + B3, and B3, respectively, p = 0.045. Twenty‐three patients experienced recurrence or metastasis. The total 10‐year progression‐free survival (PFS) rates were 86.0% overall (85.0% in type B2, 87.2% in type B2 + B3, and 87.5% in type B3). Age, R0 resection, and Masaoka–Koga stage were found to have a significant on PFS in all patients. There was no statistically significant difference in PFS between different histotypes of thymoma, p = 0.650. PFS was predicted by R0 resection in all histotypes and by the Masaoka–Koga stage in the type B2 subgroup. Conclusion: Combining the two staging methods to guide the diagnosis and treatment of patients with B2 + B3 thymoma is recommended. R0 resection is recommended to reduce recurrence. Patients with B2 + B3 thymoma have a prognosis similar to those with a B2 thymoma or a B3 thymoma alone. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway.
- Author
-
Cao, Lei, Liu, Hongsheng, Huang, Cheng, Guo, Chao, Zhao, Luo, Gao, Chao, Xu, Yuan, Wang, Guige, Liang, Naixin, and Li, Shanqing
- Subjects
- *
LUNG cancer , *CANCER invasiveness , *CELLULAR signal transduction , *CANCER cell migration , *POLYMERASE chain reaction - Abstract
Background: With the rapidly increasing morbidity and mortality, lung cancer has been considered one of the serious malignant tumors, affecting millions of patients globally. Currently, the pathogenesis of lung cancer remains unclear, hindering the development of effective treatment. This study aims to investigate the mechanisms of lung cancer and develop an effective therapeutic approach for intervention in preventing lung cancer progress. Methods: The USP5 levels are detected in lung cancerous and paracancerous tissue by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting methods to explore their roles in lung cancer progression. MTT, colony assay, and transwell chamber approaches are employed to measure cell viability, proliferation, and migration, respectively. Further, flow cytometry experiments are performed to examine the effect of USP5 on lung cancer. Finally, the investigations in vivo are executed using the mice subcutaneous tumor model to identify the effect of USP5 in promoting lung cancer development. Results: Notably, USP5 is highly expressed in lung cancer, USP5 overexpression promoted the proliferation and migration in the lung cancer cell lines, H1299 and A549, while knockdown of USP5 inhibited these via regulating the PARP1-mediated mTOR signaling pathway. Furthermore, the subcutaneous tumors model was established in C57BL/6 mice, and the volume of subcutaneous tumors was significantly reduced after silencing USP5, while increased after USP5 overexpression and decreased significantly with shRARP1 treatment at the same time. Conclusions: Together, USP5 could promote the progression of lung cancer cells by mTOR signaling pathway and interacting with PARP1, indicating that USP5 may become a new target for lung cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Predictive value of clinical characteristics on risk and prognosis of synchronous brain metastases in small‐cell lung cancer patients: A population‐based study.
- Author
-
Zhou, Gang, Zhang, Zhiyuan, Yu, Peng, Geng, Ruixuan, Wang, Guige, Ma, Wenbin, Gao, Jun, Zheng, Zhibo, and Li, Yongning
- Subjects
- *
CANCER patients , *LUNG cancer , *BONE metastasis , *SMALL cell lung cancer - Abstract
Background: Patients with small‐cell lung cancer (SCLC) have a high incidence of synchronous brain metastases (SBM) and a poor prognosis, which causes a heavy burden of morbidity and mortality. A better understanding of the demographic and tumor‐specific characteristics of these patients is critical to guiding clinical practice. The purpose of this study was to investigate the predictive and prognostic value of the clinical characteristics of SCLC patients with SBM at initial diagnosis. Methods: This is a retrospective study based on the data in the latest Surveillance, Epidemiology, and End Results (SEER) version which was released in 2021 for patients diagnosed with SCLC in the presence or absence of SBM from 2010 to 2018. Multivariable logistic regression was performed to identify predictors of the presence of SBM at the initial diagnosis. Kaplan–Meier curves and multivariable Cox regression models were built to compare the prognosis of patients with different clinical characteristics and treatments. Results: A total of 33,169 SCLC patients were enrolled in this study, including 5711 (17.2%) patients with SBM and 27,458 (82.8%) patients without SBM. Patients who are black(HR = 1.313, 95% CI = 1.167–1.478, p < 0.001), higher T stage (T2, HR = 1.193, 95%CI = 1.065–1.348, p = 0.005; T3, HR = 1.169, 95%CI = 1.029–1.327, p = 0.016; T4, HR = 1.259, 95%CI = 1.117–1.418, p < 0.001), lung metastases (HR = 1.434, 95%CI = 1.294–1.588, p < 0.001) and bone metastases (HR = 1.311, 95% CI = 1.205–1.426, p < 0.001) had greater odds of SBM at initial diagnosis. The median overall survival (OS) for SCLC patients with SBM was 5.0 months. Multivariable Cox regression revealed that age ≥ 65 (HR = 1.164, 95% CI = 1.086–1.247, p < 0.025), singled (HR = 1.095, 95% CI = 1.020–1.174, p = 0.012), higher T stage (T3, HR = 1.265, 95% CI = 1.123–1.425, p < 0.001; T4, HR = 1.192, 95% CI = 1.066–1.332, p = 0.002), higher N stage (N2, HR = 1.347, 95%CI = 1.214–1.494, p < 0.001; N3, HR = 1.452, 95%CI = 1.292–1.632, p < 0.001), liver metastases (HR = 1.415, 95%CI = 1.306–1.533, p < 0.001), and bone metastases (adjusted HR = 1.126, 95%CI = 1.039–1.221, p = 0.004). Analysis of treatment regimens showed that patients who received combinational treatment exhibited longer OS than chemotherapy or radiotherapy alone, and surgery combined with chemotherapy and radiotherapy exhibited the longest OS. Conclusions: In this study, we identified risk factors for SBM in SCLC patients and prognostic indicators among this patient population. We also found that patients who received different therapeutic strategies exhibited significant difference on OS, which will provide evidence‐based support for treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis‐related genes.
- Author
-
Diao, Xiayao, Guo, Chao, Liu, Lei, Wang, Guige, and Li, Shanqing
- Subjects
- *
STATISTICS , *LOG-rank test , *MULTIVARIATE analysis , *LUNG tumors , *FISHER exact test , *T-test (Statistics) , *GENE expression profiling , *DESCRIPTIVE statistics , *CHI-squared test , *KAPLAN-Meier estimator , *TUMOR markers , *DATA analysis software , *SQUAMOUS cell carcinoma , *LONGITUDINAL method - Abstract
Background: Lung squamous cell carcinoma (LUSC), one of the main pathological types of lung cancer, has led to consequential socioeconomic burden. Ferroptosis is an iron‐dependent form of cell death process with potentials for therapeutic target in various kinds of tumors. However, whether ferroptosis‐related genes (FRGs) are associated with the prognosis of LUSC patients is still unclear. The aim of this study was to establish a FRGs‐based signature which could stratify patients with LUSC. Methods: The RNA sequencing profiles and corresponding clinical data of LUSC patients were retrieved from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) dataset. A FRG‐based signature was developed using the TCGA‐LUSC cohort and validated in the GEO cohort. Gene set enrichment analysis (GSEA) and analysis of immune cell characteristics were conducted to assess the relationship between FRGs and biological function or immune status. A nomogram based on selected clinical factors and the risk scores which were generated from the FRG‐based signature was developed using the TCGA cohort and validated in the GEO cohort. Results: A set of 16 FRGs, significantly associated with overall survival (OS) in the TCGA cohort, was identified and could classify LUSC patients into two risk groups. Kaplan–Meier analysis illustrated that the survival rate of the high‐risk group was significantly lower than the low‐risk group. Assessment and external validation of the signature showed that the survival predictive performance of this signature was adequate. Additionally, multiple pathways and functions were enriched through GSEA and the analysis of immune cell characteristics showed significantly different abundances of immune cells among the two risk groups. Finally, a nomogram integrating the FRG‐based signature and selected clinical factors was also developed and assessed in both the TCGA and GEO cohort. Conclusion: This study indicated the association between the FRGs and prognosis of patients with LUSC. Targeting ferroptosis may serve as a novel potential therapeutic alternative for LUSC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Analysis of clinicopathological features of primary diaphragm tumors: A single‐center study.
- Author
-
Guo, Chao, Liu, Lei, Zhang, Jiaqi, Wang, Guige, Chen, Yeye, Huang, Cheng, Liu, Hongsheng, and Li, Shanqing
- Subjects
- *
ACQUISITION of data methodology , *DIAPHRAGM (Anatomy) , *PLASTIC surgery , *RETROSPECTIVE studies , *SURGERY , *PATIENTS , *CANCER patients , *MEDICAL records , *MUSCLE tumors , *SYMPTOMS - Abstract
Background and Objectives: Primary diaphragm tumors are rare. The aim of this study was to explore the clinicopathological features of primary diaphragm tumor patients who underwent surgical treatment in our center to improve the diagnosis and treatment of this disease. Methods: Clinical data of patients with primary diaphragm tumor who underwent surgery in our hospital from 2004 to 2019 were reviewed and analyzed. Results: A total of 18 patients were enrolled. The male:female ratio was 8:10, and the median age was 58 years old (35–74 years old). Most patients included in this study had no typical clinical symptoms. Nine tumor cases were distributed in the left and right diaphragms separately, whereas 11 cases were located at the diaphragm angle. The diaphragm of 12 patients was reconstructed by direct suture. All postoperative pathologies showed that the tumors were benign, and cysts were observed in most of the cases (5/18). Conclusions: There are no difference in distribution of gender and distribution on both sides of the diaphragm. In addition, primary diaphragm tumor is common in middle‐age patients. Most cases occur in the diaphragm angle and are characterized by cyst lesions. Surgical resection is an effective treatment option for primary diaphragm tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Extended thymectomy with blood vessel resection and reconstruction improves therapeutic outcome for clinical stage III thymic carcinoma patients: a real-world research.
- Author
-
Liu, Lei, Zhang, Jiaqi, Wang, Guige, Guo, Chao, Chen, Yeye, Huang, Cheng, and Li, Shanqing
- Subjects
- *
THYMECTOMY , *BLOOD vessels , *OPERATIVE surgery , *PROGRESSION-free survival , *TREATMENT effectiveness , *CARCINOMA , *THYMUS tumors , *CARDIOVASCULAR surgery , *BLOOD-vessel tumors , *VENA cava superior , *THORACIC surgery , *RETROSPECTIVE studies , *METASTASIS , *TUMOR classification - Abstract
Objectives: We examine the therapeutic efficacy of extended thymectomy with blood vessel resection and reconstruction in thymic carcinoma patients with great vessel invasion.Methods: In total 26 patients diagnosed as clinical stage III thymic carcinoma with severe great vessel invasion were enrolled in this retrospective study. Among these patients, 14 cases received adjuvant chemo- and radiotherapy (non-operation subgroup, NOG), the other 12 patients received extended thymectomy with vessel resection and reconstruction followed by the adjuvant treatment (operation subgroup, OG).Results: All surgical procedures went smoothly with no perioperative death. R0 resection was obtained in all surgical cases, and we also observed a lymph node metastasis rate of 38.8%. The overall survival (OS) was 34 months for the whole cohort, 48 and 26 months for the OG and NOG respectively (p = 0.013). The median disease metastasis free survival (DMFS) was 47 months for the OG and 18 months for the NOG (p = 0.019).Conclusion: Extended thymectomy with vessel resection is feasible for patients with clinical stage III thymic carcinoma. Surgery significantly improves the overall survival and the prognosis of clinical stage III thymic carcinoma. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Clinical characteristics of resected solitary ground‐glass opacities: Comparison between benign and malignant nodules.
- Author
-
Qin, Yingzhi, Xu, Yuan, Ma, Dongjie, Tian, Zhenhuan, Huang, Cheng, Zhou, Xiaoyun, He, Jia, Liu, Lei, Guo, Chao, Wang, Guige, Zhang, Jiaqi, Wang, Yanqing, and Liu, Hongsheng
- Subjects
- *
BRONCHOGRAPHY , *COUGH , *LUNG tumors , *SMOKING , *POSITRON emission tomography , *SYMPTOMS - Abstract
Background: The management of ground‐glass opacities (GGOs) depends mainly on personal experience. In clinical practice, benign GGOs are not rare in resected specimens, for which operations may be avoided. We retrospectively compared the clinical features of resected GGOs to identify differential diagnostic characteristics. Methods: Among 1456 patients with suspected malignant GGOs who underwent surgical resection, 105 patients (35 with benign GGOs and 70 matched controls with malignant GGOs) were included. Clinical characteristics, including demographics and radiologic, surgical and pathologic characteristics, were collected. Results: The smoking index (P = 0.044), frequency of coughing (P = 0.026), GGO size (P = 0.003), size change during follow‐up (P = 0.011), location (P = 0.022), presence of air bronchogram sign (P = 0.004), distance to the pleura (P = 0.021) and positron emission tomography/computed tomography (PET/CT) appearance (P = 0.003) showed significant differences between the benign and malignant groups. Pathologically, the resected benign GGOs included focal fibrosis (17), inflammation or infection (seven), lymphoproliferative disorder (one), hamartoma (three), inflammatory myofibroblastic tumor (two), hemangioma or vascular malformation (two), endometriosis (two) and pulmonary cyst (one). Conclusions: A higher smoking index, coughing, larger size, similar or increased size during follow‐up, location in the upper and middle lobes, air bronchogram sign on CT, lesion margin to pleura distance over 1 cm, and malignant tendency on PET/CT reports were associated with malignant GGOs. Relatively active surgical interventions could be considered for GGOs highly suspected of malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.